PEPG
PepGen Inc.
$2.52
-6.67%
2026-10-23
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Key Fundamentals
Forward P/E
-2.50
EPS (TTM)
$-1.00
ROE
-75.5%
Profit Margin
0.0%
Debt/Equity
13.46
Price/Book
1.50
Beta
1.97
Market Cap
$179.4M
Avg Volume (10D)
616K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$3.57
60D Low
$1.71
Avg Volume
939K
Latest Close
$2.52
Get breakout alerts for PEPG
Sign up for Breakout Scanner to receive daily notifications when PEPG triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
PepGen Inc. (PEPG) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PEPG daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PEPG operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.